html Omega-3 and heart health: triglycerides, blood pressure, vessels and cardiovascular events
Content based on scientific studies and verifiable data.Updated: September 2026
Cardiovascular evidence

Omega-3 and heart health: outcomes that can be measured.

Cardiovascular evidence spans several areas: risk markers, vascular function, cardiac physiology, imaging and clinical outcomes. The key is to interpret each result in the context of the dose, formulation and population studied.

Five areas

What changed in the studies

The figures below come from the cardiovascular presentation, which brings together meta-analyses, randomized trials and imaging studies.

TG

Triglycerides

90 RCTs · 72,598 participants. The meta-analysis found a dose-response relationship; the effect was more evident above 2 g/day in groups with hyperlipidemia.

PA

blood pressure

71 trials · 4,973 adults. At 2–3 g/day of EPA+DHA, the average reduction was about 2.6 mmHg systolic and 1.6–1.8 mmHg diastolic.

FMD

endothelial function

32 studies · 2,385 participants. Flow-mediated dilation improved on average by +0,8% versus controlo.

FC

heart rate

51 RCTs · ~3,000 participants. Mean reduction of 2,23 bpm with EPA+DHA e 2,47 bpm in trials using DHA alone.

Cardiovascular effects do not stand alone: they directly intersect with triglycerides, metabolism and liver, with a chronic low-grade inflammation and with the long-term outcomes discussed in longevity and older adults.

Key cardiovascular benefits

From biomarker to clinical event: where omega-3 showed benefit

Results appear across risk factors, vascular function, cardiac structure and cardiovascular events.

TG

Triglycerides

Meta-analyses show a dose-response reduction, with a more evident effect at higher doses and in people with elevated triglycerides.

PA

blood pressure

Average reductions in systolic and diastolic blood pressure were observed in meta-analyses of randomized trials.

FMD

endothelial function

Improved flow-mediated dilation, a sign of better blood-vessel response.

FC

heart rate

Pooled trials showed lower heart rate, especially in studies using DHA.

♥

Plaque and remodelling

EVAPORATE and OMEGA-REMODEL showed measurable changes in coronary plaque, remodeling and post-infarction fibrosis.

↓

Cardiovascular events

Large trials and meta-analyses reported reductions in myocardial infarction, coronary events, revascularization and other outcomes in specific populations.

Cardiac imaging

Changes observed, not merely inferred

Some trials directly tracked coronary plaque and heart structure.

EVAPORATE

Coronary plaque

In 80 statin-treated patients with coronary atherosclerosis and elevated triglycerides, 4 g/day of icosapent ethyl for 18 months reduced low-attenuation plaque volume by 17%; in the placebo group, volume increased 109%.

PMID 32860032 →Related scientific study
OMEGA-REMODEL

Post-MI

In 358 patients after acute myocardial infarction, six months of high-dose omega-3 were associated with 5,8% additional reduction in left-ventricular end-systolic volume index and 5,6% reduction in non-infarct myocardial fibrosis.

PMID 27482002 →Related scientific study
Omega-3 Index

Higher level, lower risk

In the observational studies brought together in the presentation, higher red-blood-cell EPA+DHA levels were associated with lower cardiovascular risk, including signals from Framingham and pooled cohorts.

Large cohorts and clinical trials converge on a more complete picture of the role of EPA+DHA status in cardiovascular health.

Major trials

Cardiovascular events in large trials

Large trials make it possible to compare results across different doses, formulations and clinical profiles.

GISSI-P

RR 0,47 for sudden death at 4 months in 11,323 patients after myocardial infarction.

PMID 11999724 →Related scientific study

JELIS

19% lower major coronary events in the population studied.

PMID 17398308 →Related scientific study

REDUCE-IT

25% lower in the primary cardiovascular endpoint with icosapent ethyl in the high-risk population studied.

PMID 30415628 →Related scientific study

GISSI-HF

9% lower total mortality in the heart-failure trial.

PMID 18757090 →Related scientific study
Practical interpretation: dose, formulation and duration help explain the magnitude of the observed results.
Primary prevention

What VITAL showed

In VITAL, 25,871 adults received 1 g/day of marine omega-3 and were followed for cardiovascular outcomes.

Total myocardial infarction

28% lower (HR 0.72) for total myocardial infarction.

Angioplasty / PCI

22% less (HR 0.78) for percutaneous coronary intervention.

Fatal myocardial infarction

50% lower (HR 0.50) for fatal myocardial infarction.

VITAL — PMID 30415637 →Related scientific study

Synthesis

When dozens of trials are pooled

The presentation highlights that results become clearer when formulation, dose and population are analyzed separately.

meta-analysis 2021

38 RCTs · 149,051 people.

−7% cardiovascular mortality · −13% nonfatal myocardial infarction · −9% coronary events · −9% revascularization.

PMID 34505026 →Related scientific study

Evidence atualizada 2024–2025

18 RCTs · 134,144 people.

−10% revascularization · −11% myocardial infarction · −8% cardiovascular death; the presentation highlights a larger magnitude in analyses of purified EPA.

How to track

The most useful approach is to combine biomarkers with clinical measures: Omega-3 Index, triglycerides, blood pressure, heart rate and, when indicated, structured medical assessment.

Understand the Omega-3 Index →
FAQ

Quick questions

Which cardiovascular outcomes have been measured with omega-3?

Triglycerides, blood pressure, endothelial function, resting heart rate, coronary plaque, post-infarction remodeling and cardiovascular events in specific populations.

What helps maximize the result?

An appropriate dose, formulation, consistency and enough time to change EPA+DHA status.

Is the Omega-3 Index related to cardiovascular risk?

Yes. Observational studies found an association between higher red-blood-cell EPA+DHA levels and lower cardiovascular risk, while clinical trials add intervention data.

Scientific evidence

In addition to the trials above, systematic reviews and large cohorts help place the results on a population scale.

  1. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999;354(9177):447-455. PMID:10465168
  2. Yokoyama M, Origasa H, Matsuzaki M, et al.; JELIS Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients: a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-1098. doi:10.1016/S0140-6736(07)60527-3. PMID:17398308
  3. Bhatt DL, Steg PG, Miller M, et al.; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792. PMID:30415628
  4. Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652. PMID:32860032
  5. Arabi SM, Bahrami LS, Rahimi R, et al. Omega-3 fatty acids and endothelial function: A GRADE-assessed systematic review and meta-analysis. Eur J Clin Invest. 2024;54(2):e14109. doi:10.1111/eci.14109. PMID:37859571
  6. Oh PC, Koh KK, Sakuma I, et al. Omega-3 fatty acid therapy dose-dependently decreased triglycerides and improved flow-mediated dilation in patients with hypertriglyceridemia. Int J Cardiol. 2014;176(3):696-702. PMID:25147070
  7. Zhang X, Ritonja JA, Zhou N, Chen BE, Li X. Omega-3 Polyunsaturated Fatty Acids Intake and Blood Pressure: A Dose-Response Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2022;11(11):e025071. doi:10.1161/JAHA.121.025071. PMID:35647665
  8. Wang T, Zhang X, Zhou N, et al. Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2023;12(11):e029512. PMID:37264945
  9. Eslick GD, Howe PRC, Smith C, Priest R, Bensoussan A. Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis. Int J Cardiol. 2009;136(1):4-16. doi:10.1016/ j.ijcard.2008.03.092. PMID:18774613
  10. Bernasconi AA, Wiest MM, Lavie CJ, Milani RV, Laukkanen JA. Effect of Omega-3 Dosage on Cardiovascular Outcomes: An Updated Meta-Analysis and Meta-Regression of Interventional Trials. Mayo Clin Proc. 2021;96(2):304-313. doi:10.1016/j.mayocp.2020.08.034. PMID:32951855
  11. Dinu M, Colombini B, Pagliai G, et al. Effects of omega-3 fatty acids on coronary revascularization and cardiovascular events: a meta-analysis. Eur J Prev Cardiol. 2024;31(15):1863-1875. doi:10.1093/eurjpc/ zwae179. PMID:38869144
  12. Harris WS, Tintle NL, Etherton MR, Vasan RS. Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart Study. J Clin Lipidol. 2018;12(3):718-727.e6. doi:10.1016/j.jacl.2018.02.010. PMID:29559306

Presentation available in the Library

Prefer this topic as a presentation?

Open the material page to view the visual version, related references and the reviewed PDF for reading or sharing.

View the Omega-3 and heart presentation →